RYTM RHYTHM PHARMACEUTICALS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1649904 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY61.0%
TTM net income YoY-0.8%
TTM EPS YoY6.1%
Revenue 3-yr CAGR65.5%
Net income 3-yr CAGR—
Margins
Gross margin88.2%
Operating margin-66.7%
Net margin-69.0%
FCF margin—
EBITDA margin—
Returns
ROE-163.7%
ROA-40.8%
ROIC (approx.)-83.0%
Asset turnover0.59x
Leverage & solvency
Liabilities / assets54.5%
Debt / equity1.17x
Current ratio2.78x
Interest coverage-10.27x
Cash quality & payout
Operating cash flow / net income0.42x
Accruals ratio-23.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $189.76M | $130.13M | $77.43M | $23.64M | $3.15M |
| Cost of revenue | $19.49M | $13.37M | $9.30M | $2.13M | $599,000 |
| Gross profit | $170.26M | $116.76M | $68.13M | $21.50M | $2.56M |
| R&D expense | $167.34M | $237.96M | $134.95M | $108.63M | $104.13M |
| SG&A expense | $194.94M | $144.30M | $117.53M | $92.03M | $68.49M |
| Operating income | -$192.02M | -$265.50M | -$184.36M | -$179.16M | -$170.06M |
| Interest expense | $20.58M | $20.60M | $13.89M | $5.20M | — |
| Pretax income | -$196.04M | -$260.26M | -$184.11M | -$181.12M | -$69.61M |
| Income tax | $497,000 | $346,000 | $564,000 | — | — |
| Net income | -$196.54M | -$260.60M | -$184.68M | -$181.12M | -$69.61M |
| EBITDA | -$191.52M | -$264.80M | -$183.46M | -$178.26M | -$169.24M |
| EPS (basic) | -3.11 | -4.34 | -3.20 | -3.47 | -1.40 |
| EPS (diluted) | -3.11 | -4.34 | -3.20 | -3.47 | -1.40 |
| Weighted avg. shares (diluted) | 64.98M | 61.00M | 57.67M | 52.12M | 49.60M |
| Balance sheet | |||||
| Cash & equivalents | $54.30M | $89.14M | $60.08M | $127.68M | $59.25M |
| Short-term investments | $334.65M | $231.43M | $215.76M | $205.61M | $235.61M |
| Receivables | $26.08M | $18.51M | $14.87M | $6.22M | $1.02M |
| Inventory | $25.75M | $18.74M | $8.62M | $2.92M | $111,000 |
| Current assets | $466.92M | $374.20M | $308.27M | $354.24M | $308.39M |
| PP&E, net | $1.10M | $632,000 | $1.34M | $2.20M | $2.81M |
| Intangibles | $5.32M | $6.17M | $7.03M | $7.88M | $4.66M |
| Total assets | $480.20M | $392.27M | $332.75M | $382.48M | $329.52M |
| Current liabilities | $105.94M | $115.52M | $55.20M | $39.81M | $43.43M |
| Short-term debt | $7.30M | $1.54M | — | — | — |
| Long-term debt | $100.89M | $108.27M | $106.14M | — | — |
| Total debt | $108.18M | $109.81M | $106.14M | — | — |
| Total liabilities | $210.17M | $227.72M | $162.99M | $118.22M | $45.37M |
| Shareholders' equity | $139.07M | $21.73M | $169.76M | $264.26M | $284.15M |
| Net debt | $53.88M | $20.67M | $46.06M | — | — |
| Shares outstanding | 67.21M | 62.39M | 59.43M | 56.61M | 50.28M |
| Cash flow statement | |||||
| Operating cash flow | -$115.67M | -$113.88M | -$136.16M | -$173.43M | -$146.00M |
| Capital expenditure | $953,000 | $0 | $47,000 | $281,000 | $434,000 |
| Free cash flow | -$116.63M | -$113.88M | -$136.20M | -$173.71M | -$146.44M |
| Investing cash flow | -$137.15M | -$48.17M | -$5.67M | $28.03M | -$62.16M |
| Financing cash flow | $217.96M | $191.24M | $74.37M | $213.83M | $166.48M |
| Depreciation & amortization | $500,000 | $700,000 | $900,000 | $896,000 | $816,000 |
| Stock-based compensation | $66.82M | $39.68M | $32.55M | $19.83M | $20.80M |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.